Regenxbio Financials - Benzinga

Regenxbio Inc

RGNXNASDAQ

Trade with Public

Trade with Public

$7.88

0.435.77%

Últ. Act.: Sep 30, 7:34 AM

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

Regenxbio Financials

Regenxbio (RGNX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Regenxbio Q2 EPS $0.43 Beats $(0.03) Estimate, Sales $108.019M Miss $117.127M Estimate

Regenxbio (NASDAQ:RGNX) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $(0.03) by 1533.33 percent. This is a 131.16 percent increase over losses of $(1.38) per share from the

Benzinga Newsdesk

PRO
Regenxbio Q1 EPS $(1.72) Misses $(1.39) Estimate, Sales $6.393M Miss $26.322M Estimate

Benzinga Newsdesk

Earnings Scheduled For May 14, 2026

Benzinga Insights

Regenxbio Earnings Report: Q4 Overview

Benzinga Insights

PRO
Regenxbio Q4 EPS $(1.30) Misses $(0.58) Estimate, Sales $30.337M Miss $36.561M Estimate.

Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(1.30) per share which missed the analyst consensus estimate of $(0.58) by 124.53 percent. This is a 28.71 percent decrease over losses of $(1.01) per share from the

Benzinga Newsdesk

Earnings Scheduled For March 5, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved